This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
by Zacks Equity Research
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
by Zacks Equity Research
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
by Zacks Equity Research
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
Here's Why Investors Should Invest in Arcturus Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
by Zacks Equity Research
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
by Zacks Equity Research
The phase III REACH study evaluating Fulcrum's losmapimod for treating facioscapulohumeral muscular dystrophy fails to meet the primary endpoint.
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
by Zacks Equity Research
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPMD
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
by Zacks Equity Research
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
by Zacks Equity Research
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study
by Zacks Equity Research
The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.
Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Illumina (ILMN)
by David Bartosiak
Big jump after earnings led by a pullback, could be an opportunity here.
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
by Zacks Equity Research
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
Should Vanguard S&P Mid-Cap 400 Value ETF (IVOV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOV
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
by Zacks Equity Research
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
by Zacks Equity Research
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
by Zacks Equity Research
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
Affimed Appoints New CEO, Shares Fall on Leadership Change
by Zacks Equity Research
AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
by Zacks Equity Research
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Corcept Shares Rise More Than 45% in Six Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.